The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model

Transfusion

Volumn 50, Issue 11, 2010, Pages 2461-2473

  Custer, Brian ^a,b,c   Agapova, Maria ^a,b,c   Martinez, Rebecca Havlir ^a,b,c  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ANALYTIC METHOD; ARTICLE; BACTERIUM; BLOOD ANALYSIS; CHIKUNGUNYA ALPHAVIRUS; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; ERYTHROCYTE TRANSFUSION; HEALTH CARE SYSTEM; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T LYMPHOTROPIC VIRUS 3; IMMUNOMODULATION; PATHOGEN REDUCTION TECHNOLOGY; PLASMA TRANSFUSION; QUALITY OF LIFE; SCREENING; SYPHILIS; TRYPANOSOMA CRUZI; WEST NILE FLAVIVIRUS;

BLOOD BANKS; BLOOD PRESERVATION; BLOOD TRANSFUSION; CANADA; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INFECTION; INFECTION CONTROL; MODELS, STATISTICAL; REGISTRIES; RIBOFLAVIN; RISK FACTORS; RISK MANAGEMENT;

EID: 78349253751     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02704.x     Document Type: Article

References (45)

1. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F,. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47: 2338 -47.
2. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F,. Pathogen inactivation: making decisions about new technologies-preliminary report of a consensus conference. Vox Sang 2007; 93: 179 -82.
3. Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, Triulzi D, Staginnus U,. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003; 25: 2464 -86.
4. Moeremans K, Warie H, Annemans L,. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 2006; 16: 17 -30.
5. Postma MJ, Van Hulst M, De Wolf JT, Botteman M, Staginnus U,. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005; 15: 379 -87.
6. Staginnus U, Corash L,. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 2004; 80: 317 -24.
7. Custer B, Hoch JS,. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009; 23: 1 -12.
8. Seghatchian J, De Sousa G,. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006; 35: 189 -96.
9. Janssen MP, Van Der Poel CL, Buskens E, Bonneux L, Bonsel GJ, Van Hout BA,. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006; 46: 956 -65.
10. Government of Canada, Statistics Canada. Canada consumer price index, health and personal care. Ottawa: Government of Canada; 2009. [cited 2009 Jan 18]. Available from: URL
11. Siegel JE, Weinstein MC, Russell LB, Gold MR,. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339 -41.
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB,. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253 -8.
13. Gauvin F, Champagne MA, Robillard P, Le-Cruguel JP, Lapointe H, Hume H,. Long-term survival rate of pediatric patients after blood transfusion. Transfusion 2008; 48: 801 -8.
14. Kamper-Jorgensen M, Ahlgren M, Rostgaard K, Melbye M, Edgren G, Nyren O, Reilly M, Norda R, Titlestad K, Tynell E, Hjalgrim H,. Survival after blood transfusion. Transfusion 2008; 48: 2577 -84.
15. Kleinman S, Marshall D, AuBuchon J, Patton M,. Survival after transfusion as assessed in a large multistate US cohort. Transfusion 2004; 44: 386 -90.
16. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME,; West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349: 1236 -45.
17. Llewelyn C, Amin M, Malfroy M, Williamson L,. Distribution of blood component recipients according to immune status. Presented at Eurosat on 19 October 2004. Transfusion Clinque et Biologique. Accessed at on 15 March 2005.
18. Vamvakas EC, Taswell HF,. Long-term survival after blood transfusion. Transfusion 1994; 34: 471 -7.
19. Wallis JP, Wells AW, Matthews JN, Chapman CE,. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion 2004; 44: 1025 -32.
20. O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC,. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007; 47: 316 -25.
21. Keil SD, Gilmour D, Miklauz MM, Goodrich RP,. Photochemical inactivation of the human hepatitis B virus using the Mirasol pathogen reduction technology (PRT) system as measured by PCR. Vox Sang 2009; 96: 2.
22. International Forum. Haemovigilance. Vox Sang 2006; 90: 34.
23. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP,. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22: 133 -53.
24. Goodrich R, Follea G, Roberts T,. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008; 48: 20a.
25. The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL Pathogen Reduction Technology. Transfusion. In Press 2010.
26. Reesink HW, Panzer S, McQuilten ZK, Wood EM, Marks DC, Wendel S, Trigo F, Biagini S, Olyntho S, Devine DV, Mumford I, Cazenave JP, Rasongls P, Garraud O, Richard P, Schooneman F, Vezon G, Al Radwan R, Brand A, Hervig T, Castro E, Lozano M, Navarro L, Puig L, Almazán C, MacLennan S, Cardigan R, Franklin IM, Prowse C,. International forum-pathogen inactivation of platelet concentrates. Vox Sang 2010;Mar 21. [Epub ahead of print].
27. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP,. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877 -85.
28. Goodrich RP, Gilmour D, Hovenga N, Keil SD,. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205 -16.
29. Cardo LJ, Salata J, Mendez J, Reddy H, Goodrich R,. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007; 37: 131 -7.
30. Solheim BG, Seghatchian J,. The six questions of pathogen reduction technology: an overview of current opinions. Transfus Apher Sci 2008; 39: 51 -7.
31. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Jay S,., Epstein JS, Goodman JL,. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematol Am Soc Hematol Educ Program 2003: 575 -89.
32. Blumberg N,. Allogeneic transfusion and infection: economic and clinical implications. Semin Hematol 1997; 34: 34 -40.
33. Vamvakas EC, Blajchman MA,. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007; 21: 327 -48.
34. Vamvakas EC,. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009; 49: 2743 -58.
35. Kleinman SH, Lelie N, Busch MP,. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49: 2454 -89.
36. Goodrich R, Custer B, Keil SD, Busch MP,. Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion. In Press 2010.
37. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC,. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28 -40.
38. Jackson BR, Busch MP, Stramer SL, AuBuchon JP,. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721 -9.
39. Ramirez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M,. Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion 2007; 47: 421 -9.
40. Laupland KB, Lee H, Gregson DB, Manns BJ,. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect 2006; 63: 124 -32.
41. Blajchman MA, Goldman M, Freedman JJ, Sher GD,. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev 2001; 15: 1 -20.
42. The SHOT Steering Group. Serious hazards of transfusion-annual report summary 2007. Manchester: SHOT; 2008.
43. O'Brien SF, Xi G, Fan W, Yi QL, Fearon MA, Scalia V, Goldman M,. Epidemiology of hepatitis B in Canadian blood donors. Transfusion 2008; 48: 2323 -30.
44. O'Brien SF, Fan W, Xi G, Yi QL, Goldman M, Fearon MA, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M, Delage G,. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion 2008; 48: 902 -9.
45. Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL,. Chagas disease and the US blood supply. Curr Opin Infect Dis 2008; 21: 476 -82.